Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 121

1.

A Prognostic Scoring System for the Prediction of Metastatic Recurrence Following Curative Resection of Pancreatic Neuroendocrine Tumors.

Sho S, Court CM, Winograd P, Toste PA, Pisegna JR, Lewis M, Donahue TR, Hines OJ, Reber HA, Dawson DW, Tomlinson JS.

J Gastrointest Surg. 2018 Oct 23. doi: 10.1007/s11605-018-4011-7. [Epub ahead of print]

PMID:
30353489
2.

Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming.

Koutsioumpa M, Hatziapostolou M, Polytarchou C, Tolosa EJ, Almada LL, Mahurkar-Joshi S, Williams J, Tirado-Rodriguez AB, Huerta-Yepez S, Karavias D, Kourea H, Poultsides GA, Struhl K, Dawson DW, Donahue TR, Fernández-Zapico ME, Iliopoulos D.

Gut. 2019 Jul;68(7):1271-1286. doi: 10.1136/gutjnl-2017-315690. Epub 2018 Oct 18.

PMID:
30337373
3.

KRASG12D and TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus scrofa Pigs.

Principe DR, Overgaard NH, Park AJ, Diaz AM, Torres C, McKinney R, Dorman MJ, Castellanos K, Schwind R, Dawson DW, Rana A, Maker A, Munshi HG, Rund LA, Grippo PJ, Schook LB.

Sci Rep. 2018 Aug 22;8(1):12548. doi: 10.1038/s41598-018-30916-6.

4.

Metformin Decreases the Incidence of Pancreatic Ductal Adenocarcinoma Promoted by Diet-induced Obesity in the Conditional KrasG12D Mouse Model.

Chang HH, Moro A, Chou CEN, Dawson DW, French S, Schmidt AI, Sinnett-Smith J, Hao F, Hines OJ, Eibl G, Rozengurt E.

Sci Rep. 2018 Apr 12;8(1):5899. doi: 10.1038/s41598-018-24337-8.

5.

Thioredoxin system-mediated regulation of mutant Kras associated pancreatic neoplasia and cancer.

Schultz MA, Diaz AM, Smite S, Lay AR, DeCant B, McKinney R, Mascarinas WE, Xia Y, Neumann C, Bentrem D, Dawson DW, Grippo PJ.

Oncotarget. 2017 Oct 4;8(54):92667-92681. doi: 10.18632/oncotarget.21539. eCollection 2017 Nov 3.

6.

Incidence of pancreatic cancer is dramatically increased by a high fat, high calorie diet in KrasG12D mice.

Chang HH, Moro A, Takakura K, Su HY, Mo A, Nakanishi M, Waldron RT, French SW, Dawson DW, Hines OJ, Li G, Go VLW, Sinnett-Smith J, Pandol SJ, Lugea A, Gukovskaya AS, Duff MO, Rosenberg DW, Rozengurt E, Eibl G.

PLoS One. 2017 Sep 8;12(9):e0184455. doi: 10.1371/journal.pone.0184455. eCollection 2017.

7.

Islet inflammation and ductal proliferation may be linked to increased pancreatitis risk in type 2 diabetes.

Schludi B, Moin ASM, Montemurro C, Gurlo T, Matveyenko AV, Kirakossian D, Dawson DW, Dry SM, Butler PC, Butler AE.

JCI Insight. 2017 Jul 6;2(13). pii: 92282. doi: 10.1172/jci.insight.92282. eCollection 2017 Jul 6.

8.

The Presence of Interleukin-13 at Pancreatic ADM/PanIN Lesions Alters Macrophage Populations and Mediates Pancreatic Tumorigenesis.

Liou GY, Bastea L, Fleming A, Döppler H, Edenfield BH, Dawson DW, Zhang L, Bardeesy N, Storz P.

Cell Rep. 2017 May 16;19(7):1322-1333. doi: 10.1016/j.celrep.2017.04.052.

9.

Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas.

Sugimoto M, Hines OJ, Dawson DW, Muthusamy VR, Reber HA, Donahue TR.

Pancreas. 2017 Apr;46(4):e32-e34. doi: 10.1097/MPA.0000000000000802. No abstract available.

10.

Direct growth-inhibitory effects of prostaglandin E2 in pancreatic cancer cells in vitro through an EP4/PKA-mediated mechanism.

Schmidt A, Sinnett-Smith J, Young S, Chang HH, Hines OJ, Dawson DW, Rozengurt E, Eibl G.

Surgery. 2017 Jun;161(6):1570-1578. doi: 10.1016/j.surg.2016.12.037. Epub 2017 Feb 20.

11.

PDX1 dynamically regulates pancreatic ductal adenocarcinoma initiation and maintenance.

Roy N, Takeuchi KK, Ruggeri JM, Bailey P, Chang D, Li J, Leonhardt L, Puri S, Hoffman MT, Gao S, Halbrook CJ, Song Y, Ljungman M, Malik S, Wright CV, Dawson DW, Biankin AV, Hebrok M, Crawford HC.

Genes Dev. 2016 Dec 15;30(24):2669-2683. doi: 10.1101/gad.291021.116.

12.

Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts.

Nguyen AH, Elliott IA, Wu N, Matsumura C, Vogelauer M, Attar N, Dann A, Ghukasyan R, Toste PA, Patel SG, Williams JL, Li L, Dawson DW, Radu C, Kurdistani SK, Donahue TR.

Oncotarget. 2017 Mar 21;8(12):19074-19088. doi: 10.18632/oncotarget.13572.

13.

Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.

Sugimoto M, Elliott IA, Nguyen AH, Kim S, Muthusamy VR, Watson R, Hines OJ, Dawson DW, Reber HA, Donahue TR.

JAMA Surg. 2017 Jan 18;152(1):e163349. doi: 10.1001/jamasurg.2016.3349. Epub 2017 Jan 18.

PMID:
27829085
14.

Allograft biopsy findings in patients with small bowel transplantation.

Koo J, Dawson DW, Dry S, French SW, Naini BV, Wang HL.

Clin Transplant. 2016 Nov;30(11):1433-1439. doi: 10.1111/ctr.12836. Epub 2016 Sep 26.

PMID:
27582272
15.

Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality.

Donahue TR, Dawson DW.

Trends Endocrinol Metab. 2016 Nov;27(11):770-781. doi: 10.1016/j.tem.2016.06.009. Epub 2016 Jul 25. Review.

16.

Association of Histopathologic Phenotype of Periampullary Adenocarcinomas With Survival.

Williams JL, Chan CK, Toste PA, Elliott IA, Vasquez CR, Sunjaya DB, Swanson EA, Koo J, Hines OJ, Reber HA, Dawson DW, Donahue TR.

JAMA Surg. 2017 Jan 1;152(1):82-88. doi: 10.1001/jamasurg.2016.3466.

PMID:
27732711
17.

Gemcitabine Activates Natural Killer Cells to Attenuate Pancreatic Cancer Recurrence.

Dawson DW, Fernandez-Zapico ME.

Gastroenterology. 2016 Aug;151(2):234-7. doi: 10.1053/j.gastro.2016.06.032. Epub 2016 Jun 29. No abstract available.

18.

Loss of TGFβ signaling promotes colon cancer progression and tumor-associated inflammation.

Principe DR, DeCant B, Staudacher J, Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J, McKinney RD, Khazaie K, Pasche B, Dawson DW, Munshi HG, Grippo PJ, Jung B.

Oncotarget. 2017 Jan 17;8(3):3826-3839. doi: 10.18632/oncotarget.9830.

19.

Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms: A Multicenter Study.

Moris M, Dawson DW, Jiang J, Lewis J, Nassar A, Takeuchi KK, Lay AR, Zhai Q, Donahue TR, Kelly KA, Crawford HC, Wallace M.

Pancreas. 2016 Oct;45(9):1353-8. doi: 10.1097/MPA.0000000000000652.

20.

TGFβ Signaling in the Pancreatic Tumor Microenvironment Promotes Fibrosis and Immune Evasion to Facilitate Tumorigenesis.

Principe DR, DeCant B, Mascariñas E, Wayne EA, Diaz AM, Akagi N, Hwang R, Pasche B, Dawson DW, Fang D, Bentrem DJ, Munshi HG, Jung B, Grippo PJ.

Cancer Res. 2016 May 1;76(9):2525-39. doi: 10.1158/0008-5472.CAN-15-1293. Epub 2016 Mar 15.

21.

Chemotherapy-Induced Inflammatory Gene Signature and Protumorigenic Phenotype in Pancreatic CAFs via Stress-Associated MAPK.

Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, Tran LM, Bikhchandani M, Li L, Patel SG, Dawson DW, Donahue TR.

Mol Cancer Res. 2016 May;14(5):437-47. doi: 10.1158/1541-7786.MCR-15-0348. Epub 2016 Mar 15.

22.

Long-term survival in patients with pancreatic ductal adenocarcinoma.

Stark AP, Sacks GD, Rochefort MM, Donahue TR, Reber HA, Tomlinson JS, Dawson DW, Eibl G, Hines OJ.

Surgery. 2016 Jun;159(6):1520-1527. doi: 10.1016/j.surg.2015.12.024. Epub 2016 Feb 2.

23.

Robust Early Inflammation of the Peripancreatic Visceral Adipose Tissue During Diet-Induced Obesity in the KrasG12D Model of Pancreatic Cancer.

Hertzer KM, Xu M, Moro A, Dawson DW, Du L, Li G, Chang HH, Stark AP, Jung X, Hines OJ, Eibl G.

Pancreas. 2016 Mar;45(3):458-65. doi: 10.1097/MPA.0000000000000497.

24.

Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease.

Williams JL, Nguyen AH, Rochefort M, Muthusamy VR, Wainberg ZA, Dawson DW, Tomlinson JS, Hines OJ, Reber HA, Donahue TR.

J Surg Oncol. 2015 Sep;112(4):396-402. doi: 10.1002/jso.24011. Epub 2015 Aug 25.

PMID:
26303811
25.

Calcipotriol Targets LRP6 to Inhibit Wnt Signaling in Pancreatic Cancer.

Arensman MD, Nguyen P, Kershaw KM, Lay AR, Ostertag-Hill CA, Sherman MH, Downes M, Liddle C, Evans RM, Dawson DW.

Mol Cancer Res. 2015 Nov;13(11):1509-19. doi: 10.1158/1541-7786.MCR-15-0204. Epub 2015 Jul 29.

26.

Pancreatic cancer patient survival correlates with DNA methylation of pancreas development genes.

Thompson MJ, Rubbi L, Dawson DW, Donahue TR, Pellegrini M.

PLoS One. 2015 Jun 3;10(6):e0128814. doi: 10.1371/journal.pone.0128814. eCollection 2015.

27.

p85α is a microRNA target and affects chemosensitivity in pancreatic cancer.

Toste PA, Li L, Kadera BE, Nguyen AH, Tran LM, Wu N, Madnick DL, Patel SG, Dawson DW, Donahue TR.

J Surg Res. 2015 Jun 15;196(2):285-293. doi: 10.1016/j.jss.2015.02.071. Epub 2015 Mar 6.

28.

Brg1 promotes both tumor-suppressive and oncogenic activities at distinct stages of pancreatic cancer formation.

Roy N, Malik S, Villanueva KE, Urano A, Lu X, Von Figura G, Seeley ES, Dawson DW, Collisson EA, Hebrok M.

Genes Dev. 2015 Mar 15;29(6):658-71. doi: 10.1101/gad.256628.114.

29.

Mutant KRAS-induced expression of ICAM-1 in pancreatic acinar cells causes attraction of macrophages to expedite the formation of precancerous lesions.

Liou GY, Döppler H, Necela B, Edenfield B, Zhang L, Dawson DW, Storz P.

Cancer Discov. 2015 Jan;5(1):52-63. doi: 10.1158/2159-8290.CD-14-0474. Epub 2014 Oct 31.

30.

Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition.

Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR.

Clin Cancer Res. 2015 Jan 1;21(1):157-65. doi: 10.1158/1078-0432.CCR-14-0610. Epub 2014 Oct 27.

31.

Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma.

Chen R, Dawson DW, Pan S, Ottenhof NA, de Wilde RF, Wolfgang CL, May DH, Crispin DA, Lai LA, Lay AR, Waghray M, Wang S, McIntosh MW, Simeone DM, Maitra A, Brentnall TA.

Lab Invest. 2015 Jan;95(1):43-55. doi: 10.1038/labinvest.2014.128. Epub 2014 Oct 27.

32.

Mucinous cystic neoplasms of the pancreas: are we overestimating malignant potential?

Nguyen D, Dawson DW, Hines OJ, Reber HA, Donahue TR.

Am Surg. 2014 Oct;80(10):915-9.

PMID:
25264629
33.

Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriac H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, Donahue TR, Masamune A, Shimosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM.

Cell. 2014 Sep 25;159(1):80-93. doi: 10.1016/j.cell.2014.08.007.

34.

The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.

Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, Dawson DW.

Mol Cancer Ther. 2014 Oct;13(10):2303-14. doi: 10.1158/1535-7163.MCT-13-1005. Epub 2014 Jul 31.

35.

The chromatin regulator Brg1 suppresses formation of intraductal papillary mucinous neoplasm and pancreatic ductal adenocarcinoma.

von Figura G, Fukuda A, Roy N, Liku ME, Morris Iv JP, Kim GE, Russ HA, Firpo MA, Mulvihill SJ, Dawson DW, Ferrer J, Mueller WF, Busch A, Hertel KJ, Hebrok M.

Nat Cell Biol. 2014 Mar;16(3):255-67. doi: 10.1038/ncb2916. Epub 2014 Feb 23.

36.

Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.

Kadera BE, Sunjaya DB, Isacoff WH, Li L, Hines OJ, Tomlinson JS, Dawson DW, Rochefort MM, Donald GW, Clerkin BM, Reber HA, Donahue TR.

JAMA Surg. 2014 Feb;149(2):145-53. doi: 10.1001/jamasurg.2013.2690.

PMID:
24306217
37.

Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.

Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, Donahue TR.

J Gastrointest Surg. 2013 Dec;17(12):2105-13. doi: 10.1007/s11605-013-2360-9. Epub 2013 Oct 8.

PMID:
24101447
38.
39.

MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.

Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR.

PLoS One. 2013 Aug 22;8(8):e71978. doi: 10.1371/journal.pone.0071978. eCollection 2013.

40.

High-fat, high-calorie diet promotes early pancreatic neoplasia in the conditional KrasG12D mouse model.

Dawson DW, Hertzer K, Moro A, Donald G, Chang HH, Go VL, Pandol SJ, Lugea A, Gukovskaya AS, Li G, Hines OJ, Rozengurt E, Eibl G.

Cancer Prev Res (Phila). 2013 Oct;6(10):1064-73. doi: 10.1158/1940-6207.CAPR-13-0065. Epub 2013 Aug 13.

41.

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors.

Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC.

Diabetes. 2013 Jul;62(7):2595-604. doi: 10.2337/db12-1686. Epub 2013 Mar 22.

42.

WNT7B mediates autocrine Wnt/β-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma.

Arensman MD, Kovochich AN, Kulikauskas RM, Lay AR, Yang PT, Li X, Donahue T, Major MB, Moon RT, Chien AJ, Dawson DW.

Oncogene. 2014 Feb 13;33(7):899-908. doi: 10.1038/onc.2013.23. Epub 2013 Feb 18.

43.

HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma.

Nguyen Kovochich A, Arensman M, Lay AR, Rao NP, Donahue T, Li X, French SW, Dawson DW.

Cancer. 2013 Feb 1;119(3):529-39. doi: 10.1002/cncr.27725. Epub 2012 Aug 22.

44.

Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma.

Mann KM, Ward JM, Yew CC, Kovochich A, Dawson DW, Black MA, Brett BT, Sheetz TE, Dupuy AJ; Australian Pancreatic Cancer Genome Initiative, Chang DK, Biankin AV, Waddell N, Kassahn KS, Grimmond SM, Rust AG, Adams DJ, Jenkins NA, Copeland NG.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):5934-41. doi: 10.1073/pnas.1202490109. Epub 2012 Mar 15.

45.

Integrative survival-based molecular profiling of human pancreatic cancer.

Donahue TR, Tran LM, Hill R, Li Y, Kovochich A, Calvopina JH, Patel SG, Wu N, Hindoyan A, Farrell JJ, Li X, Dawson DW, Wu H.

Clin Cancer Res. 2012 Mar 1;18(5):1352-63. doi: 10.1158/1078-0432.CCR-11-1539. Epub 2012 Jan 18.

46.

Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma.

Biechele TL, Kulikauskas RM, Toroni RA, Lucero OM, Swift RD, James RG, Robin NC, Dawson DW, Moon RT, Chien AJ.

Sci Signal. 2012 Jan 10;5(206):ra3. doi: 10.1126/scisignal.2002274.

47.

Wilms tumor gene on X chromosome (WTX) inhibits degradation of NRF2 protein through competitive binding to KEAP1 protein.

Camp ND, James RG, Dawson DW, Yan F, Davison JM, Houck SA, Tang X, Zheng N, Major MB, Moon RT.

J Biol Chem. 2012 Feb 24;287(9):6539-50. doi: 10.1074/jbc.M111.316471. Epub 2012 Jan 3.

48.

Dysregulation of Wnt/β-catenin signaling in gastrointestinal cancers.

White BD, Chien AJ, Dawson DW.

Gastroenterology. 2012 Feb;142(2):219-32. doi: 10.1053/j.gastro.2011.12.001. Epub 2011 Dec 8. Review.

49.

Nodal/Activin signaling: a novel target for pancreatic cancer stem cell therapy.

Donahue TR, Dawson DW.

Cell Stem Cell. 2011 Nov 4;9(5):383-4. doi: 10.1016/j.stem.2011.10.006.

50.

Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer.

Li A, King J, Moro A, Sugi MD, Dawson DW, Kaplan J, Li G, Lu X, Strieter RM, Burdick M, Go VL, Reber HA, Eibl G, Hines OJ.

Am J Pathol. 2011 Mar;178(3):1340-9. doi: 10.1016/j.ajpath.2010.11.058.

Supplemental Content

Loading ...
Support Center